Translink Corporate Finance announced the sale of Centaur Healthcare Limited (trading as “Surepharm”), a contract development manufacturing organisation predominantly servicing the pharmaceutical market, to Chiltern Capital, an ambitious and active private equity investor in the UK lower mid-market. Souters Investments and Bluester Capital co-invested alongside Chiltern with debt financing being provided by Thincats.

Surepharm provides a wide range of services from pilot plant facilities for formulation development and pre-production trials to outsourced development, manufacturing and packaging of its products for its customers in the UK and overseas. From its fully licensed and high tech facilities, Surepharm specialises in producing solid dose tablets and capsules including controlled drugs, niche medicines and specials for the human and veterinary markets.

Chiltern’s investment will support Surepharm to expand the capacity and capabilities of the company to drive faster growth and enhance its formulation and development offerings. Through the provision of funding for capex investment into new dosage forms alongside the development of the sales and marketing functions, Surepharm will develop its capability to provide an end-to-end service for both new and existing customers.

At Translink we are aware that the pharmaceuticals and healthcare market is very active and continues to provide exceptional investment opportunities for investors. Our healthcare experience across many countries/continents means we are ideally positioned in all markets to help other healthcare companies and investors accomplish their strategic M&A goals.